Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?

被引：0
|
作者：
Riaz, N. [1 ]
Baschnagel, A. [2 ]
Adkins, D. [3 ]
Rao, S. [1 ]
Huang, J. [3 ]
Chen, P. [2 ]
Ley, J. [3 ]
Krauss, D. [2 ]
Thorstad, W. [3 ]
Lee, N. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Beaumont Hosp, Royal Oak, MI USA
[3] Washington Univ, St Louis, MO USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 87卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2013.06.204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 32 条
  • [1] Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LAHNSCC): Can HPV Help Decide Which Agent?
    Riaz, N.
    Baschnagel, A.
    Adkins, D.
    Rao, S.
    Huang, J.
    Chen, P.
    Ley, J.
    Krauss, D.
    Thorstad, W.
    Lee, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 472 - 472
  • [2] Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
    Sheth, S.
    Bauman, J. R.
    Deal, A.
    Chera, B.
    Shen, C.
    Galloway, T.
    Hackman, T.
    Blumberg, J.
    Yarbrough, W.
    Weissler, M.
    Hilliard, C.
    Mehra, R.
    Grilley-Olson, J.
    Weiss, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Outcomes of concurrent radiation with cisplatin versus cetuximab in locally-advanced head and neck squamous cell carcinoma (LAHNSCC).
    Ly Viet Do
    Dowlatshahi, Morteza
    Parekh, Zayd
    Trevino, Richard
    Eng, Richard
    Fann, Karen
    Dinh, Ngon
    Lee, Raymond W.
    Lee, Charlene Sen-Yee
    Hla, Tin T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT)
    Liu, C. S.
    Elser, C.
    Huang, S.
    Pond, G. R.
    O'Sullivan, B.
    Chen, E. X.
    Waldron, J. N.
    Goldstein, D.
    Siu, L. L.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Lim, Yoojoo
    Keam, Bhumsuk
    Koh, Youngil
    Lee, Kyung-Hun
    Kim, Tae Min
    Lee, Se-Hoon
    Hah, Jeong-Hun
    Kwon, Tack-Kyun
    Kim, Dong-Wan
    Wu, Hong-Gyun
    Sung, Myung-Whun
    Heo, Dae Seog
    Kim, Kwang Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Machiels, Jean -Pascal H.
    Licitra, Lisa
    Rischin, Danny
    Waldron, John
    Burtness, Barbara
    Gregoire, Vincent
    Shekar, Tulin
    Brown, Holly M.
    Cheng, Jonathan D.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A randomized controlled multi-centered trial
    He, X.
    Yin, H.
    Guo, W.
    Sun, X.
    Hu, X.
    Yan, P.
    Li, F.
    Huang, S.
    Zhou, H.
    Zhang, F.
    Wang, B.
    Bian, X.
    Wei, Q.
    Wu, J.
    Wang, F.
    Song, D.
    Liu, J.
    Zhou, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin, and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC)
    Kuperman, D. I.
    Nussenbaum, B.
    Thorstad, W.
    Haughey, B.
    Lewis, J.
    Adkins, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Concurrent chemoradiotherapy using carboplatin/cetuximab regimen in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) not eligible for high-dose cisplatin (HD-DDP)
    Saigal, Kunal
    Warsch, Sean
    Mandalia, Amar
    Samuels, Michael
    Tolba, Khaled A.
    Ikpeazu, Chukwuemeka
    Kwon, Deukwoo
    Santos, Edgardo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Koh, Youngil
    Lee, Keun-Wook
    Kim, Sung-Bae
    Park, Kyong Hwa
    Shin, Sang Won
    Kang, Jin Hyoung
    Keam, Bhumsuk
    Lee, Se-Hoon
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1234